Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02580552 |
Recruitment Status :
Completed
First Posted : October 20, 2015
Last Update Posted : November 23, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF) Chronic Lymphocytic Leukemia (CLL) Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype Adult T-Cell Leukemia/Lymphoma (ATLL) | Drug: Cobomarsen | Phase 1 |
Study Design:
- Part A: Cohorts of 3-6 patients diagnosed with MF will receive up to five intratumoral injections of cobomarsen over a period of up to 15 days with follow-up for an additional 20 days, beginning with the maximum deliverable intratumoral dose. Doses may be decreased in subsequent cohorts to determine the minimum pharmacodynamically active dose.
- Parts B-F: Patients in these parts of the study will be diagnosed with MF (Parts B and C), CLL (Part D), DLBCL (Part E), or ATLL (Part F). All patients will receive subcutaneous or intravenous cobomarsen (or a combination of systemic and intratumoral administration for MF patients only) on Days 1, 3 and 5, and will continue dosing on a weekly schedule until the patient becomes intolerant, develops clinically significant side effects, progresses, or the trial is terminated. Doses administered will not exceed a dose level predicted to be safe based on all prior treatment experience with the drug. Patients in Part B may continue on a stable background therapy for their disease during their treatment with cobomarsen, while patients in Parts C-F will be treated with cobomarsen alone.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 66 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias |
Actual Study Start Date : | February 9, 2016 |
Actual Primary Completion Date : | October 6, 2020 |
Actual Study Completion Date : | October 6, 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Part A, MF
Intratumoral Injection of cobomarsen
|
Drug: Cobomarsen
Other Name: MRG-106 |
Experimental: Part B, MF
Subcutaneous, intravenous or a combination of systemic and intratumoral administration of cobomarsen with or without stable background therapy
|
Drug: Cobomarsen
Other Name: MRG-106 |
Experimental: Part C, MF
Subcutaneous or intravenous administration of cobomarsen as monotherapy
|
Drug: Cobomarsen
Other Name: MRG-106 |
Experimental: Part D, CLL
Subcutaneous or intravenous administration of cobomarsen as monotherapy
|
Drug: Cobomarsen
Other Name: MRG-106 |
Experimental: Part E, DLBCL, activated B-cell (ABC) subtype
Subcutaneous or intravenous administration of cobomarsen as monotherapy
|
Drug: Cobomarsen
Other Name: MRG-106 |
Experimental: Part F, ATLL
Subcutaneous or intravenous administration of cobomarsen as monotherapy
|
Drug: Cobomarsen
Other Name: MRG-106 |
- Safety and tolerability of cobomarsen based on vital signs, physical examination, clinical laboratory tests, ECG, and incidence and severity of adverse events [ Time Frame: From start of treatment to end of study participation ]
- Area under the plasma concentration vs. time curve (AUC) of cobomarsen following single and repeat doses administered intratumorally, subcutaneously or intravenously [ Time Frame: Up to 56 days ]
- Peak plasma concentration (Cmax) of cobomarsen following single and repeat doses administered intratumorally, subcutaneously or intravenously [ Time Frame: Up to 56 days ]
- Trough plasma concentration (Ctrough) of cobomarsen following each 4-week cycle of dosing [ Time Frame: Monthly from Week 5 up to end of study participation ]
- Skin disease severity (index lesions) - MF only [ Time Frame: Every 2 weeks from start of treatment until end of study participation ]Changes in MF skin lesion severity before and after treatment based on the Composite Assessment of Index Lesion Severity (CAILS) score
- Skin disease severity (whole body) - MF only [ Time Frame: Every 2 weeks from start of treatment until end of study participation ]Changes in MF skin lesion severity before and after treatment based on the modified Severity Weighted Assessment Tool (mSWAT) score
- Overall Response Rate in the skin - MF [ Time Frame: Approximately 1 year ]Proportion of subjects who achieve a partial response (PR) or complete response (CR) in the skin, based on SWAT score
- Overall Response Rate - CLL [ Time Frame: Approximately 1 year ]Proportion of subjects who achieve a PR or CR as defined by IWCLL criteria (Hallek et al., 2008) based on CT scans, bone marrow biopsies, and flow cytometry
- Minimal Residual Disease (MRD) - CLL only [ Time Frame: Approximately 1 year ]Proportion of subjects who achieve a CR with no evidence of MRD by flow cytometry
- Overall Response Rate - DLBCL [ Time Frame: Approximately 1 year ]Proportion of subjects who achieve a PR or CR as defined by the Lugano classification (Cheson et al., 2014) based on positron emission tomography-computed tomography (PET-CT) scans and bone marrow biopsy to confirm CR
- Overall Response Rate - ATLL [ Time Frame: Approximately 1 year ]Proportion of subjects who achieve a PR or CR as defined by international consensus criteria (Tsukasaki et al., 2009) based on CT scans and flow cytometry, and bone marrow biopsy to confirm CR
- Duration of Response [ Time Frame: Up to approximately 2 years ]Number of days from initial date of confirmed PR or CR until loss of response or relapse
- Time to Progression [ Time Frame: Up to approximately 2 years ]Number of days from first dose until objective disease progression
- Progression Free Survival (PFS) [ Time Frame: Up to approximately 2 years ]Number of days from first dose until objective disease progression or death from any cause
- Overall Survival (OS) [ Time Frame: Up to approximately 2 years ]Number of days from first dose until death from any cause
- miR-155-5p expression in cutaneous lesions of subjects with MF [ Time Frame: At baseline and between Week 16 and end of study participation ]Exploratory assessment based on quantitative real time polymerase chain reaction (qRT-PCR) analysis of total RNA isolated from skin biopsies
- Proportion of neoplastic lymphoid cells in cutaneous lesions of subjects with MF [ Time Frame: At baseline and between Week 16 and end of study participation ]Exploratory histological assessment before and after treatment with cobomarsen
- Proportions of immune cell subsets [ Time Frame: At baseline and monthly or bimonthly, up to end of study participation ]Exploratory assessment before and after treatment with cobomarsen by flow cytometry on whole blood
- Dermatology-specific quality of life - MF only [ Time Frame: At baseline and monthly, up to approximately 2 years ]Changes in skin-related quality of life based on the Skindex-29 assessment tool
- Pruritus - MF only [ Time Frame: At baseline and monthly, up to approximately 2 years ]Changes in intensity of skin itch based on the Pruritus Numerical Rating Scale
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Parts A-C only: Patients must have biopsy proven MF, clinical stage I, II, or III (excluding visceral or nodal involvement), and must be refractory to or intolerant of established therapies for their condition
- Part D only: Patients diagnosed with CLL who are intolerant to, or have disease that is relapsed/refractory after, at least two prior therapies
- Part E only: Patients with biopsy-proven DLBCL who are intolerant to, or have disease that is relapsed/refractory after, at least two prior therapies, including any anti-CD20 monoclonal antibody and chemotherapy with curative intent
- Part F only: Patients with documented HTLV-1 infection and histologically or cytologically proven ATLL of any stage, and who are intolerant to, or have disease that is relapsed/refractory after, at least one prior therapy
- Females must not be pregnant or lactating. Women of child-bearing potential must use a highly effective method of contraception throughout their study participation and for at least 6 months following the last dose of study drug.
- Males must be surgically sterile, abstinent, or if engaged in sexual relations with a female of child-bearing potential, must be willing to use a highly effective method of contraception throughout their study participation and for at least 6 months after the last dose of study drug.
Exclusion Criteria:
- Evidence of renal or liver dysfunction at screening
- Clinically significant anemia, neutropenia or thrombocytopenia at screening
- History of bleeding diathesis or coagulopathy
- Clinically significant cardiovascular disease, history of myocardial infarction within the last 6 months, or evidence of QTc interval prolongation at screening
- Serologically positive for HIV; serologically positive for Hepatitis B or Hepatitis C with evidence of liver dysfunction or documented liver cirrhosis
- Prior malignancies within the past 3 years (with allowance for adequately treated in situ carcinoma of the cervix uteri, and basal cell or localized squamous cell carcinoma of the skin treated with curative intent)
- Use of an investigational small molecule drug during the 30 days prior to screening or use of an investigational oligonucleotide or biologic drug during the prior 90 days
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02580552
Study Director: | Diana M. Escolar, MD, FAAN | miRagen Therapeutics, Inc. |
Responsible Party: | miRagen Therapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT02580552 |
Other Study ID Numbers: |
MRG106-11-101 |
First Posted: | October 20, 2015 Key Record Dates |
Last Update Posted: | November 23, 2020 |
Last Verified: | November 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Cutaneous T-cell Lymphoma CTCL Mycosis Fungoides Chronic lymphocytic leukemia CLL |
Diffuse large B-cell lymphoma DLBCL Adult T-cell leukemia/lymphoma ATLL |
Mycoses Lymphoma Leukemia Lymphoma, B-Cell Leukemia, Lymphoid Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, T-Cell Lymphoma, T-Cell, Peripheral Lymphoma, Large B-Cell, Diffuse Mycosis Fungoides Leukemia, T-Cell Leukemia-Lymphoma, Adult T-Cell Lymphoma, T-Cell, Cutaneous Neoplasms by Histologic Type |
Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Hematologic Diseases Lymphoma, Non-Hodgkin Leukemia, B-Cell Chronic Disease Disease Attributes Pathologic Processes Bacterial Infections and Mycoses Infections |